Table 2 Clinical demographics of the ISR and non-ISR groups in this study
Parameter | Total (N = 93) | ISR (N = 45) | Non-ISR (N = 48) | p value |
|---|---|---|---|---|
Age (years) | 65.71 ± 8.73 | 65.69 ± 8.82 | 65.61 ± 8.72 | 0.12 |
Gender | ||||
Male | 76 (81.72%) | 41 (91.11%) | 35 (72.92%) | – |
Female | 17 (18.28%) | 4 (8.89%) | 13 (27.08%) | – |
Smoking | 3 (3.23%) | 2 (4.44%) | 1 (2.08%) | – |
Comorbidities | ||||
Hyperlipidemia | 84 (90.32%) | 42 (93.33%) | 42 (87.50%) | 0.34 |
Hypertension | 71 (76.34%) | 33 (73.33%) | 38 (79.17%) | 0.51 |
Angina pectoris | 42 (45.16%) | 22 (48.89%) | 20 (41.67%) | – |
Diabetes | 29 (31.18%) | 15 (33.33%) | 14 (29.17%) | 0.67 |
Chronic CHF | 5 (5.38%) | 3 (6.67%) | 2 (4.17%) | – |
Medications | ||||
Aspirin | 75 (80.65%) | 40 (88.89%) | 35 (72.92%) | 0.05 |
Beta blocker | 51 (54.84%) | 29 (64.44%) | 22 (45.83%) | 0.07 |
CCBs | 30 (32.26%) | 14 (31.11%) | 16 (33.33%) | 0.82 |
ARB | 61 (65.59%) | 30 (66.67%) | 31 (64.58%) | 0.83 |
Clopidogrel | 43 (46.24%) | 15 (33.33%) | 28 (58.33%) | 0.02 |
Lipid-lowering agent | 84 (90.32%) | 41 (91.11%) | 43 (89.58%) | 0.80 |